Videx Ec
Designed to support retroviral load management to manage CD4 cell levels and alleviate risk of opportunistic infections.
- Category
- HIV Management
- Active ingredient
- Didanosine
- Route
- Oral use
- Form
- Tablet
- Strengths
- 100mg
Prescription and consultation requirements for Videx Ec vary by destination and are determined by the fulfilment partner.
Videx Ec details
- Alternative names
- didanosine
- Therapeutic class
- Nucleoside Reverse Transcriptase Inhibitor (NRTI)
- Pharmacological class
- Antiretroviral
- Contraindications
- concurrent use of allopurinol or ribavirin; severe hepatic impairment
- Minor side effects
- diarrhoea; nausea; headache
- Moderate side effects
- peripheral neuropathy; abdominal pain; elevated amylase
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Bristol-Myers Squibb
- Onset Time
- 2–4 weeks
- Duration
- 12–24 hours
- Storage instructions
- Store below 25°C. Keep dry.
- Drug interactions
- Allopurinol; Ribavirin; Tenofovir
- Age restrictions
- Approved for paediatric and adult populations.
Serious side effects
severe acute pancreatitis, requires immediate medical attention; lactic acidosis, requires immediate medical attention; severe hepatomegaly, requires immediate medical attention
Patient summary
designed to support retroviral load management to manage CD4 cell levels and alleviate risk of opportunistic infections.
Mechanism of action
Incorporates into growing viral DNA, acting as a chain terminator to prevent HIV reverse transcription.
Pregnancy and breastfeeding
TGA Category B: Generally safe. Breastfeeding: Avoid to prevent viral transmission.